Exscientia plc (NASDAQ:EXAI – Get Rating) was the recipient of a large decline in short interest in December. As of December 30th, there was short interest totalling 1,590,000 shares, a decline of 13.6% from the December 15th total of 1,840,000 shares. Based on an average trading volume of 201,400 shares, the short-interest ratio is currently 7.9 days. Approximately 1.4% of the shares of the company are sold short.
Exscientia Price Performance
Shares of EXAI traded down $0.18 during midday trading on Friday, reaching $5.85. The stock had a trading volume of 80,912 shares, compared to its average volume of 163,186. Exscientia has a 52 week low of $4.09 and a 52 week high of $22.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.55 and a quick ratio of 7.55. The firm's 50 day moving average price is $5.55 and its 200-day moving average price is $7.94. The company has a market capitalization of $718.84 million, a P/E ratio of -2.94 and a beta of -0.03.
Get
Exscientia alerts:
Exscientia (NASDAQ:EXAI – Get Rating) last announced its earnings results on Tuesday, November 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.16). The company had revenue of $8.24 million for the quarter, compared to analyst estimates of $15.83 million. Exscientia had a negative return on equity of 18.43% and a negative net margin of 405.81%. On average, analysts forecast that Exscientia will post -0.77 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Barclays cut their target price on Exscientia from $40.00 to $12.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 16th.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of EXAI. Renaissance Technologies LLC purchased a new position in shares of Exscientia during the second quarter valued at $154,000. Toroso Investments LLC purchased a new position in Exscientia in the third quarter valued at about $176,000. Raymond James & Associates purchased a new position in Exscientia in the first quarter valued at about $182,000. State Street Corp purchased a new position in Exscientia in the third quarter valued at about $235,000. Finally, Legal & General Group Plc purchased a new position in Exscientia in the second quarter valued at about $254,000. Hedge funds and other institutional investors own 22.36% of the company's stock.
About Exscientia
(Get Rating)
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection.
Featured Articles
- Get a free copy of the StockNews.com research report on Exscientia (EXAI)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Exscientia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exscientia and related companies with MarketBeat.com's FREE daily email newsletter.
